{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:40:05Z","timestamp":1786736405880,"version":"build-2736575974"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Can Res Ther"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/jcrt.jcrt_833_15","type":"journal-article","created":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T03:25:15Z","timestamp":1539746715000},"page":"110","source":"Crossref","is-referenced-by-count":10,"title":["Pediatric chronic myeloid leukemia: A single-center experience"],"prefix":"10.4103","volume":"16","author":[{"given":"Irappa","family":"Madabhavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurva","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurang","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsha","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0973-1482.243496-1","unstructured":"Ries LA, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, et al . Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995 (NIH). Bethesda, MD: National Cancer Institute, SEER Program; 1999."},{"key":"key-10.4103\/0973-1482.243496-2","first-page":"1497","volume-title":"A minute chromosome in human chronic granulocytic leukemia","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"key-10.4103\/0973-1482.243496-3","first-page":"227","volume-title":"Management of CML in the pediatric age group: Imatinib mesylate or SCT","author":"El-Alfy","year":"2010","journal-title":"J Egypt Natl Canc Inst"},{"key":"key-10.4103\/0973-1482.243496-4","first-page":"1809","volume-title":"Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European leukemiaNet","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.243496-5","first-page":"28","volume-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.243496-6","first-page":"186","volume-title":"International Randomized Study of Interferon versus STI571 (IRIS) 7-year follow-up: Sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with Imatinib (IM) [Abstract]","author":"O'Brien","year":"2008","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.243496-7","first-page":"1327","volume-title":"Chronic myelogenous leukemia, version 1.2014","author":"O'Brien","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"key-10.4103\/0973-1482.243496-8","first-page":"96","volume-title":"Changing trends of chronic myeloid leukemia in greater Mumbai, India over a period of 30 years","author":"Dikshit","year":"2011","journal-title":"Indian J Med Paediatr Oncol","ISSN":"https:\/\/id.crossref.org\/issn\/0971-5851","issn-type":"print"},{"key":"key-10.4103\/0973-1482.243496-9","first-page":"1821","volume-title":"How I treat childhood CML","author":"Andolina","year":"2012","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.243496-10","first-page":"37","volume-title":"ELN 2013 response status criteria: Relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?","author":"Etienne","year":"2015","journal-title":"Am J Hematol"},{"key":"key-10.4103\/0973-1482.243496-11","first-page":"140","volume-title":"Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia","author":"Millot","year":"2005","journal-title":"Pediatrics"},{"key":"key-10.4103\/0973-1482.243496-12","first-page":"930","volume-title":"In vitro fertilization and risk of childhood leukemia in Greece and Sweden","author":"Petridou","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"key-10.4103\/0973-1482.243496-13","first-page":"112","volume-title":"Correlation of BCR\/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia","author":"Adler","year":"2009","journal-title":"Eur J Haematol"},{"key":"key-10.4103\/0973-1482.243496-14","first-page":"85","volume-title":"Differentiation patterns in the blastic phase of chronic myeloid leukemia","author":"Griffin","year":"1983","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.243496-15","first-page":"826","volume-title":"Lymphoid blast crises of chronic myelogenous leukemia represent stages in the development of B-cell precursors","author":"Bakhshi","year":"1983","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0973-1482.243496-16","first-page":"49","volume-title":"The role of p53 mutations in the switch to blast crisis in chronic myeloid leukemia [abstract]","author":"Guinn","year":"1994","journal-title":"Br J Haematol"},{"key":"key-10.4103\/0973-1482.243496-17","first-page":"65","volume-title":"Do chromosome abnormalities determine the type of acute leukemia that develops in CML?","author":"Bernstein","year":"1990","journal-title":"Leukemia"},{"key":"key-10.4103\/0973-1482.243496-18","first-page":"721","volume-title":"Philadelphia chromosome-positive chronic myelocytic leukemia in children.Survival and prognostic factors","author":"Castro-Malaspina","year":"1983","journal-title":"Cancer"},{"key":"key-10.4103\/0973-1482.243496-19","first-page":"220","volume-title":"Adult-type CML in childhood: Case report and review","author":"Homans","year":"1984","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"key-10.4103\/0973-1482.243496-20","first-page":"1230","volume-title":"Hyperleukocytosis and leukostasis: Common features of childhood chronic myelogenous leukemia","author":"Rowe","year":"1984","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.243496-21","first-page":"994","volume-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0973-1482.243496-22","first-page":"33","volume-title":"Managing children with chronic myeloid leukaemia (CML): Recommendations for the management of CML in children and young people up to the age of 18 years","author":"de","year":"2014","journal-title":"Br J Haematol"},{"key":"key-10.4103\/0973-1482.243496-23","first-page":"368","volume-title":"Treatment of pediatric chronic myeloid leukemia in the year 2010: Use of tyrosine kinase inhibitors and stem-cell transplantation","author":"Suttorp","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"key-10.4103\/0973-1482.243496-24","first-page":"2655","volume-title":"Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a children's oncology group phase 1 study","author":"Champagne","year":"2004","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.243496-25","first-page":"2827","volume-title":"Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: Results of the French national phase IV trial","author":"Millot","year":"2011","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.243496-26","first-page":"187","volume-title":"Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation","author":"Millot","year":"2006","journal-title":"Leukemia"},{"key":"key-10.4103\/0973-1482.243496-27","first-page":"2643","volume-title":"Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood","author":"Kolb","year":"2003","journal-title":"Cancer"},{"key":"key-10.4103\/0973-1482.243496-28","first-page":"254","volume-title":"Aphase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A children's oncology group study","author":"Bond","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"key-10.4103\/0973-1482.243496-29","first-page":"839","volume-title":"Pediatric phase I trial and pharmacokinetic study of dasatinib: A report from the children's oncology group phase I consortium","author":"Aplenc","year":"2011","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.243496-30","doi-asserted-by":"crossref","unstructured":"Wayne A, Macedo C, Szczudio T, Woodman R. Nilotinib treatment in pediatric patients with Philadelphia chromosome-positive leukemia refractory to prior tyrosine kinase inhibitor (TKI) therapy: Results from nilotinib compassionate use program. Blood 2008;112.","DOI":"10.1182\/blood.V112.11.4264.4264"},{"key":"key-10.4103\/0973-1482.243496-31","first-page":"3496","volume-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.243496-32","first-page":"e25","volume-title":"Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty","author":"Giona","year":"2013","journal-title":"Haematologica"},{"key":"key-10.4103\/0973-1482.243496-33","first-page":"766","volume-title":"Dysregulation of bone remodeling by imatinib mesylate","author":"Vandyke","year":"2010","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.243496-34","first-page":"1177","volume-title":"Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib","author":"Schmid","year":"2009","journal-title":"Haematologica"},{"key":"key-10.4103\/0973-1482.243496-35","first-page":"676","volume-title":"Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia","author":"Shima","year":"2011","journal-title":"J Pediatr"},{"key":"key-10.4103\/0973-1482.243496-36","first-page":"2538","volume-title":"Long-term imatinib therapy promotes bone formation in CML patients","author":"Fitter","year":"2008","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.243496-37","first-page":"1148","volume-title":"Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH\/IGF-1 axis","author":"Narayanan","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"key-10.4103\/0973-1482.243496-38","first-page":"120","volume-title":"TK inhibitor treatment disrupts growth hormone axis: Clinical observations in children with CML and experimental data from a juvenile animal model","author":"Ulmer","year":"2013","journal-title":"Klin Padiatr"},{"key":"key-10.4103\/0973-1482.243496-39","first-page":"1005","volume-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia","author":"Porkka","year":"2008","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.243496-40","first-page":"2460","volume-title":"Dasatinib in children and adolescents with relapsed or refractory leukemia: Results of the CA180-018 phase I dose-escalation study of the innovative therapies for children with cancer consortium","author":"Zwaan","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:41:24Z","timestamp":1786732884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_833_15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"alternative-id":["243496"],"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_833_15","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}